AstraZeneca
Cambridge ,
Cambridgeshire CB2 0AA
United Kingdom
- Home
- Companies
- AstraZeneca
- Products
- Model AZD2693 - Phase I - NASH
Model AZD2693 - Phase I - NASH
From Cardiovascular, Renal & Metabolism
Mechanism: NASH resolution; Area under investigation: NASH; Date commenced phase: Q4 2019; Estimated Filing Acceptance: US: EU: Japan: China. Additional information. Molecule size: Small molecule; Status change.
-
Most popular related searches
Customer reviews
No reviews were found for Model AZD2693 - Phase I - NASH. Be the first to review!